All Pharma News
Vaccinex Reports 2023 Financial Results and Provides Corporate Update

Vaccinex Reports 2023 Financial Results and Provides Corporate Update
GLOBENEWSWIRE
02 Apr 2024
Share Share
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering

Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering
GLOBENEWSWIRE
27 Mar 2024
Share Share
Vaccinex Announces Agreements for Access to ActivMAb® Antigen Virus Technology

Vaccinex Announces Agreements for Access to ActivMAb® Antigen Virus Technology
GLOBENEWSWIRE
21 Feb 2024
Share Share
Vaccinex, Inc. Announces Reverse Stock Split

Vaccinex, Inc. Announces Reverse Stock Split
GLOBENEWSWIRE
15 Feb 2024
Share Share
Vaccinex Announces Pricing of $3.7 Million PIPE Financing

Vaccinex Announces Pricing of $3.7 Million PIPE Financing
GLOBENEWSWIRE
07 Feb 2024
Share Share
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance

Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance
GLOBENEWSWIRE
04 Dec 2023
Share Share
Vaccinex Reports Third Quarter 2023 Financial Results

Vaccinex Reports Third Quarter 2023 Financial Results
GLOBENEWSWIRE
13 Nov 2023
Share Share
Vaccinex Reports Benefit in Analyses from two Phase 2 Studies of Pepinemab

Vaccinex Reports Benefit in Analyses from two Phase 2 Studies of Pepinemab
GLOBENEWSWIRE
31 Oct 2023
Share Share
Vaccinex Reports Effect of Pepinemab Treatment in Neurodegenerative Diseases

Vaccinex Reports Effect of Pepinemab Treatment in Neurodegenerative Diseases
GLOBENEWSWIRE
26 Oct 2023
Share Share
Vaccinex Announces Pricing of $9.6 Million Public Offering

Vaccinex Announces Pricing of $9.6 Million Public Offering
GLOBENEWSWIRE
28 Sep 2023
Share Share